Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Vifor Pharma Teams with Evotec to Form Joint Venture

Swiss company Vifor Pharma and Germany’s Evotec AG launched a joint venture to focus on the discovery and development of new therapies for kidney diseases.

Read More »

Novo Nordisk nudges up 2019 sales outlook as new drugs excel

Novo Nordisk posted third-quarter 2019 operating profit a touch below expectations on weak insulin sales and impairments, but nudged up the company’s sales outlook on hopes for new type 2 diabetes and obesity drugs.

Read More »

FDA approves Farxiga for treating heart failure risk

AstraZeneca’s blockbuster drug Farxiga won U.S. approval as a treatment to reduce the chances of hospitalization for heart failure in adults with type 2 diabetes and other cardiovascular risks.

Read More »

Janssen’s Invokana Becomes First Drug Approved in 20 Years to Slow Diabetic Kidney Disease

Invokana won U.S. approval to reduce the risk of end-stage kidney disease, cardiovascular death and worsening of kidney function in adults with type 2 diabetes and diabetic kidney disease.

Read More »

FDA approves Novo Nordisk’s oral diabetes drug

The U.S. Food and Drug Administration approved Novo Nordisk’s Rybelsus (semaglutide) tablets 7 mg or 14 mg for adults with type 2 diabetes that along with diet and exercise may improve blood sugar.

Read More »

French weight-loss pill scandal set for landmark trial

A landmark French trial will seek to settle one of the country’s biggest pharmaceutical scandals, probing whether the company behind a weight-loss drug believed to have triggered killer side effects covered up the risks.

Read More »

AstraZeneca Reports Positive Results in Late-Stage Trials for Brilinta, Farxiga

AstraZeneca reported positive results from clinical trial programs for Brilinta and Farxiga, causing stock to jump 3.4 percent.

Read More »

Cutting back on vegetable protein tied to unhealthy aging

Older adults who cut back on the amount of vegetable protein in their diets may be more likely to experience age-related health problems than their peers who increase the amount of plant protein they eat, a Spanish study suggests.

Read More »

Lexicon Posts Positive 52-Week Pooled Zynquista Data in Type 1 Diabetes

Shares of Texas-based Lexicon Pharmaceuticals shot up after the company announced positive 52-week cardiorenal data from a pooled analysis of the type 1 diabetes trials Tandem1 and Tandem2.

Read More »

Novo Nordisk’s new diabetes, obesity drugs lift sales outlook

Novo Nordisk’s sales forecast for 2019 was raised due to growing demand for obesity products and a new injectable treatment for diabetes, which is now the company’s growth engine as insulin sales decline.

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

October 2019 Focus: Top 50 Company Profiles & Financials, Outcomes Creativity Index, and more!

Subscribe

Ad Right Bottom